Literature DB >> 28476269

Barriers to and facilitators of pharmacotherapy for alcohol use disorder in VA residential treatment programs.

Andrea K Finlay1, Laura S Ellerbe2, Jessie J Wong3, Christine Timko4, Anna D Rubinsky5, Shalini Gupta6, Thomas R Bowe7, Jennifer L Burden8, Alex H S Harris9.   

Abstract

Among US military veterans, alcohol use disorder (AUD) is prevalent and in severe cases patients need intensive AUD treatment beyond outpatient care. The Department of Veterans Affairs (VA) delivers intensive, highly structured addiction and psychosocial treatment through residential programs. Despite the evidence supporting pharmacotherapy among the effective treatments for AUD, receipt of these medications (e.g., naltrexone, acamprosate) among patients in residential treatment programs varies widely. In order to better understand this variation, the current study examined barriers and facilitators to use of pharmacotherapy for AUD among patients in VA residential treatment programs. Semi-structured qualitative interviews with residential program management and staff were conducted and the Consolidated Framework for Implementation Research was used to guide coding and analysis of interview transcripts. Barriers to use of pharmacotherapy for AUD included cultural norms or philosophy against prescribing, lack of access to willing prescribers, lack of interest from leadership, and perceived lack of patient interest or need. Facilitators included cultural norms of openness or active promotion of pharmacotherapy; education for patients, program staff and prescribers; having prescribers on staff, and care coordination within residential treatment and with other clinic settings in and outside VA. Developing and testing improvement strategies to increase care coordination and consistent support from leadership may also yield increases in the use of pharmacotherapy for AUD among residential patients. Published by Elsevier Inc.

Entities:  

Keywords:  Alcohol dependence; Alcohol-related disorders; Pharmacotherapy; Residential treatment; Veterans

Mesh:

Substances:

Year:  2017        PMID: 28476269      PMCID: PMC5467688          DOI: 10.1016/j.jsat.2017.03.005

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  17 in total

Review 1.  Content analysis and thematic analysis: Implications for conducting a qualitative descriptive study.

Authors:  Mojtaba Vaismoradi; Hannele Turunen; Terese Bondas
Journal:  Nurs Health Sci       Date:  2013-03-11       Impact factor: 1.857

2.  Pharmacotherapy of alcohol use disorders by the Veterans Health Administration: patterns of receipt and persistence.

Authors:  Alex H S Harris; Elizabeth Oliva; Thomas Bowe; Keith N Humphreys; Daniel R Kivlahan; Jodie A Trafton
Journal:  Psychiatr Serv       Date:  2012-07       Impact factor: 3.084

3.  Topiramate in the treatment of alcohol dependence: a meta-analysis.

Authors:  B Arbaizar; T Diersen-Sotos; I Gómez-Acebo; J Llorca
Journal:  Actas Esp Psiquiatr       Date:  2010-01-01       Impact factor: 1.196

Review 4.  Barriers to use of pharmacotherapy for addiction disorders and how to overcome them.

Authors:  Elizabeth M Oliva; Natalya C Maisel; Adam J Gordon; Alex H S Harris
Journal:  Curr Psychiatry Rep       Date:  2011-10       Impact factor: 5.285

5.  Alcohol and drug use disorders among homeless veterans: prevalence and association with supported housing outcomes.

Authors:  Jack Tsai; Wesley J Kasprow; Robert A Rosenheck
Journal:  Addict Behav       Date:  2013-02-16       Impact factor: 3.913

6.  Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science.

Authors:  Laura J Damschroder; David C Aron; Rosalind E Keith; Susan R Kirsh; Jeffery A Alexander; Julie C Lowery
Journal:  Implement Sci       Date:  2009-08-07       Impact factor: 7.327

Review 7.  Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?

Authors:  Natalya C Maisel; Janet C Blodgett; Paula L Wilbourne; Keith Humphreys; John W Finney
Journal:  Addiction       Date:  2012-10-17       Impact factor: 6.526

8.  How are substance use disorders addressed in VA psychiatric and primary care settings? Results of a national survey.

Authors:  Stephen W Tracy; Jodie A Trafton; Kenneth R Weingardt; Eangelica G Aton; Keith Humphreys
Journal:  Psychiatr Serv       Date:  2007-02       Impact factor: 3.084

9.  Pharmacotherapy for alcohol dependence: perceived treatment barriers and action strategies among Veterans Health Administration service providers.

Authors:  Alex H S Harris; Laura Ellerbe; Rachelle N Reeder; Thomas Bowe; Adam J Gordon; Hildi Hagedorn; Elizabeth Oliva; Anna Lembke; Daniel Kivlahan; Jodie A Trafton
Journal:  Psychol Serv       Date:  2013-01-28

Review 10.  Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis.

Authors:  Daniel E Jonas; Halle R Amick; Cynthia Feltner; Georgiy Bobashev; Kathleen Thomas; Roberta Wines; Mimi M Kim; Ellen Shanahan; C Elizabeth Gass; Cassandra J Rowe; James C Garbutt
Journal:  JAMA       Date:  2014-05-14       Impact factor: 56.272

View more
  8 in total

1.  Inpatient adoption of medications for alcohol use disorder: A mixed-methods formative evaluation involving key stakeholders.

Authors:  Paul J Joudrey; Benjamin J Oldfield; Kimberly A Yonkers; Patrick G O'Connor; Gretchen Berland; E Jennifer Edelman
Journal:  Drug Alcohol Depend       Date:  2020-06-02       Impact factor: 4.492

2.  Attitudes about medications for alcohol use disorder among individuals with serious mental illness: A health belief model analysis.

Authors:  Elizabeth Bromley; Derjung M Tarn; Michael McCreary; Brian Hurley; Allison J Ober; Katherine E Watkins
Journal:  J Subst Abuse Treat       Date:  2020-04-20

3.  Association Between Gabapentin Receipt for Any Indication and Alcohol Use Disorders Identification Test-Consumption Scores Among Clinical Subpopulations With and Without Alcohol Use Disorder.

Authors:  Christopher T Rentsch; David A Fiellin; Kendall J Bryant; Amy C Justice; Janet P Tate
Journal:  Alcohol Clin Exp Res       Date:  2019-02-03       Impact factor: 3.455

4.  Barriers and Facilitators to Implementation of Pharmacotherapy for Opioid Use Disorders in VHA Residential Treatment Programs.

Authors:  Andrea K Finlay; Jessie J Wong; Laura S Ellerbe; Anna Rubinsky; Shalini Gupta; Thomas R Bowe; Eric M Schmidt; Christine Timko; Jennifer L Burden; Alex H S Harris
Journal:  J Stud Alcohol Drugs       Date:  2018-11       Impact factor: 2.582

5.  Influence of comorbid drug use disorder on receipt of evidence-based treatment for alcohol use disorder among VA patients with alcohol use disorder and Hepatitis C and/or HIV.

Authors:  Madeline C Frost; Theresa E Matson; Judith I Tsui; Emily C Williams
Journal:  Drug Alcohol Depend       Date:  2018-10-30       Impact factor: 4.492

6.  Barriers to Medications for Opioid Use Disorder Among Veterans Involved in the Legal System: a Qualitative Study.

Authors:  Andrea K Finlay; Erica Morse; Matthew Stimmel; Emmeline Taylor; Christine Timko; Alex H S Harris; David Smelson; Mengfei Yu; Jessica Blue-Howells; Ingrid A Binswanger
Journal:  J Gen Intern Med       Date:  2020-06-24       Impact factor: 5.128

Review 7.  Strategies to increase implementation of pharmacotherapy for alcohol use disorders: a structured review of care delivery and implementation interventions.

Authors:  Emily C Williams; Theresa E Matson; Alex H S Harris
Journal:  Addict Sci Clin Pract       Date:  2019-02-12

8.  Central amygdala mineralocorticoid receptors modulate alcohol self-administration.

Authors:  Viren H Makhijani; Preethi Irukulapati; Kalynn Van Voorhies; Brayden Fortino; Joyce Besheer
Journal:  Neuropharmacology       Date:  2020-09-29       Impact factor: 5.250

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.